13F Holdings
中文EN

EDIT Editas Medicine, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650664 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.4%
TTM net income YoY63.9%
TTM EPS YoY77.0%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-151.7%
Net margin-145.0%
FCF margin-221.7%
EBITDA margin-147.5%

Returns

ROE-147.4%
ROA-34.3%
ROIC (approx.)—
Asset turnover0.24x

Leverage & solvency

Liabilities / assets61.5%
Debt / equity0.67x
Current ratio2.82x
Interest coverage-10.58x

Cash quality & payout

Operating cash flow / net income1.53x
Accruals ratio18.0%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$40.52M$32.31M$78.12M$19.71M$25.54M
R&D expense$89.95M$199.25M$177.65M$174.96M$142.51M
SG&A expense$49.90M$71.99M$69.65M$70.70M$76.18M
Operating income-$160.01M-$251.15M-$169.18M-$225.95M-$193.15M
Interest expense$2.13M$0———
Income tax$0$0$0$0$0
Net income-$160.06M-$237.09M-$153.22M-$220.43M-$192.50M
EBITDA-$154.73M-$245.34M-$163.12M-$219.61M-$188.09M
EPS (basic)-1.80-2.88-2.02-3.21-2.85
EPS (diluted)-1.80-2.88-2.02-3.21-2.85
Weighted avg. shares (diluted)88.75M82.34M75.97M68.66M67.62M
Balance sheet
Cash & equivalents$146.65M$135.42M$127.53M$141.52M$207.40M
Short-term investments$0$138.37M$199.46M$202.75M$296.33M
Receivables$15.18M$16.27M$10.19M$5.14M$267,000
Current assets$163.90M$289.31M$340.83M$356.75M$507.31M
PP&E, net$3.54M$14.50M$12.03M$15.57M$17.12M
Total assets$186.53M$341.59M$499.15M$514.32M$677.48M
Current liabilities$46.25M$77.22M$63.22M$60.11M$46.88M
Short-term debt$5.00M$5.00M$0——
Long-term debt$53.60M$52.43M$0——
Total debt$58.60M$57.43M$0——
Total liabilities$159.25M$207.31M$150.06M$153.64M$123.84M
Shareholders' equity$27.29M$134.27M$349.10M$360.68M$553.64M
Net debt-$88.04M-$77.98M-$127.53M——
Shares outstanding97.87M82.73M81.77M68.85M68.44M
Cash flow statement
Operating cash flow-$165.24M-$210.28M-$132.18M-$177.35M-$163.80M
Capital expenditure$607,000$8.83M$4.72M$4.12M$7.98M
Free cash flow-$165.85M-$219.11M-$136.90M-$181.47M-$171.78M
Investing cash flow$138.67M$162.15M-$3.73M$114.07M-$54.47M
Financing cash flow$40.47M$56.03M$118.04M$1.28M$282.11M
Depreciation & amortization$5.28M$5.81M$6.06M$6.34M$5.05M
Stock-based compensation$10.00M$21.42M$19.80M$29.29M$43.40M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.